Hosono / Chatal | Resistance to Ibritumomab in Lymphoma | Buch | sack.de

Hosono / Chatal Resistance to Ibritumomab in Lymphoma



Softcover Nachdruck of the original 1. Auflage 2018, Band: 18, 158 Seiten, Kartoniert, Previously published in hardcover, Format (B × H): 155 mm x 235 mm, Gewicht: 273 g Reihe: Resistance to Targeted Anti-Cancer Therapeutics
ISBN: 978-3-030-08652-7
Verlag: Springer, Berlin


Hosono / Chatal Resistance to Ibritumomab in Lymphoma

This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab.

Zielgruppe


Research

Weitere Infos & Material


1. Clinical Use and Efficacy of Ibritumomab in B-cell Lymphoma 2. Biology and Pathology of B-cell lymphoma 3. Resistance to Y-90 Ibritumomab Tiuxetan Therapy 4. Features of Ibritumomab as Radionuclide Therapy 5. Radiological Evaluation of Response and Resistance of Ibritumomab 6. Characteristics of Ibritumomab as Radionuclide Therapy Agent 7. Resistance and Heterogeneity of Intratumoral Antibody Distribution 8. Radiation Dosimetry in Ibritumomab Therapy 9. Combining RAIT and immune-based therapies to overcome resistance in cancer? 10. Prospects for enhancing efficacy of radioimmunotherapy Index


Hosono, Makoto
Makoto Hosono, MD, PhD, is a Professor of Radiology and Nuclear Medicine, Institute of Advanced Clinical Medicine, Kindai University Faculty of Medicine, Japan, and serves as a member of Committee 3, International Commission on Radiological Protection. 
Jean-François Chatal, MD, PhD, is an Emeritus Professor of Nuclear Medicine at the University of Nantes, France. He is one of the international leaders who developed radioimmunotherapy, that is, therapy using radiolabeled anti-tumor antibodies. He created and headed an INSERM  research laboratory and also initiated the installation of a cyclotron institute termed ARRONAX for the production of novel radionuclides for nuclear medicine.


WIR VERWENDEN COOKIES

Einige Cookies sind notwendig für den Betrieb der Seite, während andere uns helfen, Ihnen ein optimales Erlebnis unserer Webseite zu ermöglichen.